Press Release

Digbi Health in the news

Featured Press

pin

Digbi Health Launches GLP-Fit™ Program: Expands its Precision Biology Platform to Incorporate GLP-1 based Personalized Care for Obesity

PALO ALTO, Calif., September 28, 2023 – (BUSINESS WIRE)-- Digbi Health, the leader in precision biology-based telehealth care for three of the top four healthcare costs - Obesity, T2D, and Digestive Health - announced today the launch of its latest innovation in obesity care, Digbi GLP-Fit™, a scientifically-backed approach to identify the best treatment path for an individual to prevent and treat obesity.  Key Highlights: Digbi GLP-Fit™  uses the science of precision biology to identify the best treatment path for obesity for an individual with 87% accuracy, which may include 1) only precision nutrition, 2) a combination of precision nutrition and lower-cost drugs like Metformin, or 3) a combination of precision nutrition and GLP-1 medications. For Pharmacy Benefit Managers (PBMs), Digbi GLP-Fit™ streamlines prior authorization processes for GLP-1 obesity management drugs, eliminating member frustration, generating multi-million dollar savings, and creating goodwill for health plans and employers. Digbi GLP-Fit™ program guarantees 100% financial ROI, providing immediate and tangible savings for employers, PBMs, and health plans, all while ensuring optimal and medically safe patient care. The Science Behind Digbi GLP-Fit(™) This clinically proven approach integrates genetics, gut microbiome, and Continuous Glucose Monitoring (CGM) insights to recommend the best path for care and deliver personalized, clinically effective obesity treatment programs. Unlike other digital programs that rely exclusively on behavior change, Digbi GLP-Fit™  is based on recognition by the National Institutes of Health (NIH)  and medical research institutions like Harvard Health that genetics account for up to 80% of the risk of obesity and that an individual's insulin resistance and gut-microbiome are essential factors in addressing obesity. Digbi GLP-Fit™ integrates telehealth and precision nutrition based on genetics, gut microbiome, and insulin metabolism. Sustainable, Effective, and High-Quality Care This personalized approach offers tremendous savings for employers and payers. Digbi's program ensures that individuals are not unnecessarily on lifelong GLP-1 treatments, aligning with Digbi Health's prevention and effective care mission. With a Google rating of 4.8 stars, Digbi Health stands out for its unwavering commitment to delivering a high-quality member experience. "We believe in the power of precision biology and full-spectrum obesity care, which includes anti-obesity medications only when necessary. Recognizing that everyone does not respond the same way to food and medicine, Digbi is committed to making obesity care personalized, preventive, and holistic," said Ranjan Sinha, CEO of Digbi Health. "Payers and employers want to partner with us because our unique approach delivers the best obesity solution that is clinically safe and financially sustainable.” Novo Nordisk's Global Prevention Accelerator Program recently selected Digbi to pilot-test solutions for preventing obesity and related cardiometabolic conditions.   True Personalization: The 5-Point  Digbi GLP-Fit™ Program Difference While other digital providers tout personalization, Digbi GLP-Fit delivers the following advanced capabilities: Precision Diagnostics: Incorporates genetics, gut microbiome, and Continuous Glucose Monitoring (CGM) to provide a comprehensive bio-digital twin view of an individual's health. Risk Assessment: Evaluate the patient's obesity risk embedded in their genetics, gut microbiome, and insulin metabolism. Three hundred gene variants are used to develop and monitor a polygenic risk score for weight regain. Precision Biology-Based  Lifestyle Support: The FDA requires GLP drugs to have nutrition and lifestyle support. Proven and Patented De-prescription Path: Develops clinically safe,  sustainable, personalized tapering off-plan for GLP drugs. Gut Microbiome Informed Care: GLP is a gut hormone that regulates appetite, metabolism, and insulin secretion. Recent studies have shown that the gut microbiome may play a role in the effectiveness of GLP-1 drugs. With Digbi GLP-Fit™, the gut microbiome is monitored every 120 days. A longer tapering period is considered if the gut microbiome has not shifted to a less obesogenic state. Media Contact: Beverly Ibarrolan; beverly@digbihealth.com About Digbi Health Digbi Health is leading through innovation, offering a holistic solution for treating Obesity, Cardiometabolic, and Digestive disorders—three of healthcare's top 4 costly conditions. Our Precision Biology approach uses genetics, gut microbiome, Abbott CGM, and pharmaceuticals only when necessary to create personalized care programs that slash medication dependency and healthcare costs. We are on a mission to make chronic illness optional. Learn more at: www.digbihealth.com  

Ranjan Sinha
29 September, 2023
pin

Digbi Health launches Digbi Digestive™, the first gut microbiome and genetic-based digital care program to address IBS and functional digestive disorders affecting 70M Americans.

Digbi Digestive was launched based on a recent real-world outcomes study of members reversing digestive disorders. MOUNTAIN VIEW, Calif. June 16, 2021 -- Overwhelming research now links gut microbiome to mental health, sleep disorders, chronic pain, inflammatory digestive and skin illnesses along with chronic lifestyle illnesses including diabetes and obesity. Digbi Health, the first company with a clinically proven digital genetics and gut-microbiome therapeutic platform program launches Digbi Digestive, a precision care program designed to improve, reverse and monitor gastrointestinal and functional bowel disorders by prescribing food and lifestyle as medicine. Many functional gastrointestinal disorders disproportionately impact women and Caucasians. Digbi Digestive starts with analyzing a member's genetics, gut microbiome, meals, habits, clinical markers of sugar and fat in the blood, to isolate inflammatory interactions and develop deeper understanding of metabolic pathways supported by the gut microbiome like serotonin production which regulates sleep and mental health. Members have direct access to gastrointestinal health trained health coaches for personal nutrition support and guidance with meal planning. The program includes live coaching sessions for managing cravings, stress, and sleep. Members can additionally access ongoing gut microbiome monitoring services and personalized prebiotics. “Gastrointestinal diseases beyond being expensive to payers, employers and individuals are whisper illnesses that are stigmatized and linked to mental health and inflammatory illnesses that seriously affect a person’s quality of life,” said Ranjan Sinha, Founder and CEO, Digbi Health. “We are committed to address the stigma associated with these illnesses and appreciate the support provided to us by payers, TPAs, medical universities, and employers who are enabling no cost or low-cost access to their members and employees. The results of weight loss and disease reversal in our members’ outcomes are the driving forces for making Digbi Digestive available to consumers who cannot access the program through their insurance or employers” Below are the results of the recent real-world study conducted across members of a large insurance payer who experienced improvement of symptoms after Digbi intervention: 83% experienced reduction or reversal of Irritable Bowel Syndrome (IBS) 67% experienced reduction or reversal of Depression 82% experienced reduction or reversal of Heartburn 89% experienced reduction or reversal of Chronic Bloating 77% experienced reduction or reversal of Gassiness 78% experienced reduction or reversal of Chronic Constipation 79% experienced reduction or reversal of Diarrhea "Functional Bowel disorders such as irritable bowel syndrome (IBS) are complex, multifactorial illnesses that arise from the interactions between a person’s genetic, gut microbiome risk profile and lifestyle risk factors, such as stress, insufficient sleep, inflammatory food intake, excessive caloric intake, and medications. Current treatment options may not always take all these factors into consideration", said Dr. Parambir S. Dulai, a gastroenterologist at UC San Diego Medical Center. “The Digbi Health program connects these factors to deliver improved patient health on an individualized basis." “I thought I was eating all the foods that were healthy, but turns out, not for me. I also learned I’m gluten-sensitive and never believed this was a thing until I made changes to my diet. The results have been astounding. I was living with chronic gut and digestive issues and now no longer suffer and have been able to get off my medications,” said Digbi member, Anna K. Learn more about Digbi Digestive. Video by Digbi Health About Digbi Health Digbi Health is a first-of-its-kind precision digital therapeutics company that offers a prescription-grade digitally enabled personalized obesity and obesity-related gut, skin disorders, hypertension and other cardiometabolic health management programs based on an individual’s gut biome, genetic risks, blood markers, and lifestyle factors. Digbi Health is prescribed by doctors, health care providers, and insurance companies.Follow us on LinkedIn, Twitter, Instagram, and Facebook.

Aniiket Sengar
16 June, 2021
pin

Digbi Health - WVU in a research partnership to explore the relationship between personalized postoperative weight loss, genetics, and the gut microbiome

At Digbi Health, we continue to look for better solutions in personalized wellness and care. To this effect, we are proud to announce an upcoming research collaboration with The West Virginia University Medicine Medical and WVU Bariatrics Surgical Weight-Loss Program. The study will utilize Digbi Health’s personalized digital therapeutics platform to better understand the role of the gut microbiome and human genetics in postoperative weight loss and maintenance. The clinical pilot will evaluate the effectiveness of Digbi Health’s obesity management digital program personalized to each bariatric surgery patient, one-year post sleeve gastrectomy. It will be fine-tuned based on the patient’s lifestyle, genetics, and gut microbiome risks to assist with weight loss as well as maintaining a healthy weight. Through this collaboration with WVU Medical, we aim to further explore the critical importance of personalized nutrition and its direct impact on people suffering from obesity and associated metabolic illnesses. A long-term solution for Obesity Obesity is a complex metabolic disease and an ongoing global epidemic, with associated inflammatory, digestive, musculoskeletal, skin morbidities. Moreover, it is a risk factor for diabetes, cardiovascular disease, COVID-19, and could lead to reduced life expectancy. Bariatric surgery is an effective long-term intervention for morbid obesity. Yet, to reap the best outcomes from bariatric surgery, the patients need to make lifelong healthy changes in eating patterns. Social support is also a major factor in making the changes stick. Research indicates that individuals’ genetic and gut microbiome are intrinsically linked to their metabolism. Digbi Cares’ personalized meal plans and nutrition guidelines are curated to an individual’s genetic and gut microbiome markers, thus contributing to successful post-op weight loss and helping with weight maintenance. Nova Szoka MD, FACS, FASMBS, Assistant Professor at J.W. Ruby Memorial Hospital, WVU Bariatrics Surgical Weight-Loss Center is the principal investigator of the study. Dr. Skoza has said that “WVU Bariatrics is excited to partner with Digbi Health to better understand how genomic, gut microbiome, and metabolomic factors can contribute to successful weight loss following bariatric surgery.”

Aniiket Sengar
29 December, 2020

Latest Press

Digbi Health Launches GLP-Fit™ Program: Expands its Precision Biology Platform to Incorporate GLP-1 based Personalized Care for Obesity

PALO ALTO, Calif., September 28, 2023 – (BUSINESS WIRE)-- Digbi Health, the leader in precision biology-based telehealth care for three of the top four healthcare costs - Obesity, T2D, and Digestive Health - announced today the launch of its latest innovation in obesity care, Digbi GLP-Fit™, a scientifically-backed approach to identify the best treatment path for an individual to prevent and treat obesity.  Key Highlights: Digbi GLP-Fit™  uses the science of precision biology to identify the best treatment path for obesity for an individual with 87% accuracy, which may include 1) only precision nutrition, 2) a combination of precision nutrition and lower-cost drugs like Metformin, or 3) a combination of precision nutrition and GLP-1 medications. For Pharmacy Benefit Managers (PBMs), Digbi GLP-Fit™ streamlines prior authorization processes for GLP-1 obesity management drugs, eliminating member frustration, generating multi-million dollar savings, and creating goodwill for health plans and employers. Digbi GLP-Fit™ program guarantees 100% financial ROI, providing immediate and tangible savings for employers, PBMs, and health plans, all while ensuring optimal and medically safe patient care. The Science Behind Digbi GLP-Fit(™) This clinically proven approach integrates genetics, gut microbiome, and Continuous Glucose Monitoring (CGM) insights to recommend the best path for care and deliver personalized, clinically effective obesity treatment programs. Unlike other digital programs that rely exclusively on behavior change, Digbi GLP-Fit™  is based on recognition by the National Institutes of Health (NIH)  and medical research institutions like Harvard Health that genetics account for up to 80% of the risk of obesity and that an individual's insulin resistance and gut-microbiome are essential factors in addressing obesity. Digbi GLP-Fit™ integrates telehealth and precision nutrition based on genetics, gut microbiome, and insulin metabolism. Sustainable, Effective, and High-Quality Care This personalized approach offers tremendous savings for employers and payers. Digbi's program ensures that individuals are not unnecessarily on lifelong GLP-1 treatments, aligning with Digbi Health's prevention and effective care mission. With a Google rating of 4.8 stars, Digbi Health stands out for its unwavering commitment to delivering a high-quality member experience. "We believe in the power of precision biology and full-spectrum obesity care, which includes anti-obesity medications only when necessary. Recognizing that everyone does not respond the same way to food and medicine, Digbi is committed to making obesity care personalized, preventive, and holistic," said Ranjan Sinha, CEO of Digbi Health. "Payers and employers want to partner with us because our unique approach delivers the best obesity solution that is clinically safe and financially sustainable.” Novo Nordisk's Global Prevention Accelerator Program recently selected Digbi to pilot-test solutions for preventing obesity and related cardiometabolic conditions.   True Personalization: The 5-Point  Digbi GLP-Fit™ Program Difference While other digital providers tout personalization, Digbi GLP-Fit delivers the following advanced capabilities: Precision Diagnostics: Incorporates genetics, gut microbiome, and Continuous Glucose Monitoring (CGM) to provide a comprehensive bio-digital twin view of an individual's health. Risk Assessment: Evaluate the patient's obesity risk embedded in their genetics, gut microbiome, and insulin metabolism. Three hundred gene variants are used to develop and monitor a polygenic risk score for weight regain. Precision Biology-Based  Lifestyle Support: The FDA requires GLP drugs to have nutrition and lifestyle support. Proven and Patented De-prescription Path: Develops clinically safe,  sustainable, personalized tapering off-plan for GLP drugs. Gut Microbiome Informed Care: GLP is a gut hormone that regulates appetite, metabolism, and insulin secretion. Recent studies have shown that the gut microbiome may play a role in the effectiveness of GLP-1 drugs. With Digbi GLP-Fit™, the gut microbiome is monitored every 120 days. A longer tapering period is considered if the gut microbiome has not shifted to a less obesogenic state. Media Contact: Beverly Ibarrolan; beverly@digbihealth.com About Digbi Health Digbi Health is leading through innovation, offering a holistic solution for treating Obesity, Cardiometabolic, and Digestive disorders—three of healthcare's top 4 costly conditions. Our Precision Biology approach uses genetics, gut microbiome, Abbott CGM, and pharmaceuticals only when necessary to create personalized care programs that slash medication dependency and healthcare costs. We are on a mission to make chronic illness optional. Learn more at: www.digbihealth.com  

Ranjan Sinha
29 September, 2023

Digbi Health launches Digbi Digestive™, the first gut microbiome and genetic-based digital care program to address IBS and functional digestive disorders affecting 70M Americans.

Digbi Digestive was launched based on a recent real-world outcomes study of members reversing digestive disorders. MOUNTAIN VIEW, Calif. June 16, 2021 -- Overwhelming research now links gut microbiome to mental health, sleep disorders, chronic pain, inflammatory digestive and skin illnesses along with chronic lifestyle illnesses including diabetes and obesity. Digbi Health, the first company with a clinically proven digital genetics and gut-microbiome therapeutic platform program launches Digbi Digestive, a precision care program designed to improve, reverse and monitor gastrointestinal and functional bowel disorders by prescribing food and lifestyle as medicine. Many functional gastrointestinal disorders disproportionately impact women and Caucasians. Digbi Digestive starts with analyzing a member's genetics, gut microbiome, meals, habits, clinical markers of sugar and fat in the blood, to isolate inflammatory interactions and develop deeper understanding of metabolic pathways supported by the gut microbiome like serotonin production which regulates sleep and mental health. Members have direct access to gastrointestinal health trained health coaches for personal nutrition support and guidance with meal planning. The program includes live coaching sessions for managing cravings, stress, and sleep. Members can additionally access ongoing gut microbiome monitoring services and personalized prebiotics. “Gastrointestinal diseases beyond being expensive to payers, employers and individuals are whisper illnesses that are stigmatized and linked to mental health and inflammatory illnesses that seriously affect a person’s quality of life,” said Ranjan Sinha, Founder and CEO, Digbi Health. “We are committed to address the stigma associated with these illnesses and appreciate the support provided to us by payers, TPAs, medical universities, and employers who are enabling no cost or low-cost access to their members and employees. The results of weight loss and disease reversal in our members’ outcomes are the driving forces for making Digbi Digestive available to consumers who cannot access the program through their insurance or employers” Below are the results of the recent real-world study conducted across members of a large insurance payer who experienced improvement of symptoms after Digbi intervention: 83% experienced reduction or reversal of Irritable Bowel Syndrome (IBS) 67% experienced reduction or reversal of Depression 82% experienced reduction or reversal of Heartburn 89% experienced reduction or reversal of Chronic Bloating 77% experienced reduction or reversal of Gassiness 78% experienced reduction or reversal of Chronic Constipation 79% experienced reduction or reversal of Diarrhea "Functional Bowel disorders such as irritable bowel syndrome (IBS) are complex, multifactorial illnesses that arise from the interactions between a person’s genetic, gut microbiome risk profile and lifestyle risk factors, such as stress, insufficient sleep, inflammatory food intake, excessive caloric intake, and medications. Current treatment options may not always take all these factors into consideration", said Dr. Parambir S. Dulai, a gastroenterologist at UC San Diego Medical Center. “The Digbi Health program connects these factors to deliver improved patient health on an individualized basis." “I thought I was eating all the foods that were healthy, but turns out, not for me. I also learned I’m gluten-sensitive and never believed this was a thing until I made changes to my diet. The results have been astounding. I was living with chronic gut and digestive issues and now no longer suffer and have been able to get off my medications,” said Digbi member, Anna K. Learn more about Digbi Digestive. Video by Digbi Health About Digbi Health Digbi Health is a first-of-its-kind precision digital therapeutics company that offers a prescription-grade digitally enabled personalized obesity and obesity-related gut, skin disorders, hypertension and other cardiometabolic health management programs based on an individual’s gut biome, genetic risks, blood markers, and lifestyle factors. Digbi Health is prescribed by doctors, health care providers, and insurance companies.Follow us on LinkedIn, Twitter, Instagram, and Facebook.

Aniiket Sengar
16 June, 2021

Digbi Health - WVU in a research partnership to explore the relationship between personalized postoperative weight loss, genetics, and the gut microbiome

At Digbi Health, we continue to look for better solutions in personalized wellness and care. To this effect, we are proud to announce an upcoming research collaboration with The West Virginia University Medicine Medical and WVU Bariatrics Surgical Weight-Loss Program. The study will utilize Digbi Health’s personalized digital therapeutics platform to better understand the role of the gut microbiome and human genetics in postoperative weight loss and maintenance. The clinical pilot will evaluate the effectiveness of Digbi Health’s obesity management digital program personalized to each bariatric surgery patient, one-year post sleeve gastrectomy. It will be fine-tuned based on the patient’s lifestyle, genetics, and gut microbiome risks to assist with weight loss as well as maintaining a healthy weight. Through this collaboration with WVU Medical, we aim to further explore the critical importance of personalized nutrition and its direct impact on people suffering from obesity and associated metabolic illnesses. A long-term solution for Obesity Obesity is a complex metabolic disease and an ongoing global epidemic, with associated inflammatory, digestive, musculoskeletal, skin morbidities. Moreover, it is a risk factor for diabetes, cardiovascular disease, COVID-19, and could lead to reduced life expectancy. Bariatric surgery is an effective long-term intervention for morbid obesity. Yet, to reap the best outcomes from bariatric surgery, the patients need to make lifelong healthy changes in eating patterns. Social support is also a major factor in making the changes stick. Research indicates that individuals’ genetic and gut microbiome are intrinsically linked to their metabolism. Digbi Cares’ personalized meal plans and nutrition guidelines are curated to an individual’s genetic and gut microbiome markers, thus contributing to successful post-op weight loss and helping with weight maintenance. Nova Szoka MD, FACS, FASMBS, Assistant Professor at J.W. Ruby Memorial Hospital, WVU Bariatrics Surgical Weight-Loss Center is the principal investigator of the study. Dr. Skoza has said that “WVU Bariatrics is excited to partner with Digbi Health to better understand how genomic, gut microbiome, and metabolomic factors can contribute to successful weight loss following bariatric surgery.”

Aniiket Sengar
29 December, 2020
Press Release
pin

Digbi Health's Gut Biome and DNA-Based Weight Loss and Diabetes Management Program Launches with Blue Shield of California

Access to Personalized, Proven, Digital Therapeutics for Obesity and Diabetes Redefines Precision Care and Disease Management MOUNTAIN VIEW, Calif., Nov. 25, 2019. Digbi Health's clinically validated, personalized obesity, pre-diabetes and type 2 diabetes management program tailored to a person's DNA, gut biome, lifestyle preferences, and ethnicity is now available to Blue Shield of California members on the health plan's Wellvolution platform. A digital therapeutics and community health network that is the largest in the industry, Wellvolution was created in collaboration with Solera Health to help consumers holistically manage their health. Digbi Health's availability on the Wellvolution platform gives Blue Shield members access to a powerful, proven, DNA and gut microbiome-based precision care and personalized lifestyle medicine tool that is tailored to their unique biology and lifestyle. "Doctors and payers understand that obesity and diabetes are multifactorial diseases, and one-size-fits-all diet and exercise weight loss and diabetes programs do not deliver patient engagement and sustained health results," said Ranjan Sinha, CEO, and founder of Digbi Health. "We are the first company to operationalize a DNA and gut microbiome-based prescription-grade platform for doctors and payers to deliver weight loss and diabetes programs at scale." "Digbi Health is a strong fit for Wellvolution, which is designed to drive sustained engagement and outcomes by matching members to the program that best meets their needs," said Brenda Schmidt, CEO, Solera Health. Blue Shield of California, an innovative health insurer with 4.3 million members, launched Wellvolution in June. The digital therapeutics platform, powered by Solera, features a selection of about 70 digital health apps (out of more than 300,000 currently available in the Apple App Store), curated for clinical effectiveness and consumer preference. About Digbi Health Digbi Health is a first-of-its-kind precision digital therapeutics (pDTx) company that offers a prescription-grade digitally delivered personalized obesity and diabetes management program based on an individual's gut biome, DNA, blood markers, and lifestyle factors. Digbi Health and members of its precision care MD network are committed to empowering people to take control of their own health and wellness. Digbi Health is prescribed by doctors, health care providers, and insurance companies. Digbi Health is currently conducting three Institutional Review Board approved human studies. Learn more at www.digbihealth.com. Or follow us on LinkedIn, Facebook or Twitter.

Aniiket Sengar
30 November, 2019

Contact Us

Have any questions? Please feel free
to reach out and contact us

Email

Powered by science

We know why you’re here. You saw the word “science” and your heart took a little extra beat, didn’t it? you’re the patient who prints out articles to take to your doctor’s office. You scour the latest studies for the newest developments in nutrition, weight loss, and fitness.